Bioeq announces Coherus as marketing and distribution partner for its biosimilar to Lucentis (ranibizumab) in the United States
The agreement brings US patients a promise to get closer to Bioeq's leading Lucentis? biosimilar for the treatment of retinal diseases -
ZURICH,?November?7?, 2019?/ PRNewswire / - Bioeq IP AG ("Bioeq") announced today that it has signed a licensing and development agreement with Coherus BioSciences, Inc. ("Coherus" Nasdaq:?CHRS?), under which Coerus will?exclusively market and distribute?Bioeq's biosimilar candidate for Lucentis? (ranibizumab) in the?United States?.
Bioeq will remain responsible for submitting the application as a Biologics License Application (BLA) to the US Food and Drug Administration in the fourth quarter of 2019 and for subsequent product delivery.?Coherus plans to launch the 2021 product.
Hannes Teissl, board member of Bioeq commented as follows the agreement: "We are proud Coherus as our partner of choice for the?US?to have won.?This agreement marks an important milestone in providing US patients with a more affordable, highly effective treatment option for retinal diseases, including age-related macular degeneration. "
Under the terms of the agreement, Bioeq receives prepayments, regulatory payments and milestone payments, as well as a share of the profits.
Bioeq?board member?Nicola Mikulcik?commented on the plans for the future: "By 2020, Bioeq will also be able to provide marketing and distribution partners outside of the?US with?rights to its biosimilar ranibizumab."
Notes to editors
Lucentis???is a registered trademark of Genentech, Inc. It is a biopharmaceutical product containing the monoclonal antibody ranibizumab, which is used for eye diseases such as neovascular ("wet") age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy is approved. In the?United States?the annual sales of Lucentis at around $ 1.8 billion.?1
Biosimilars??are designed to replace existing branded biologics for the treatment of a range of chronic and often life-threatening diseases, with the potential to reduce costs and increase patient access.?Biosimilars have proven analytical and clinical similarity with their respective brand reference products.
Bioeq??is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Str?ngmann Group.?Bioeq develops, licenses and markets biosimilars.
www.bioeq.ch??
Coherus BioSciences?is a leading biosimilar company developing and marketing high quality therapeutics for the most important regulated markets.?Coherus is a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, distribution and marketing, and clinical-regulatory development, positioning it as a leader in the global biosimilar market.?Coherus sells UDENYCA????(pegfilgrastim-cbqv) in the?United States?and has the approval for UDENYCA???received in the European Union.?For more information,?visit www.coherus.com?.
1. The reported US sales of CHF 1,798 million correspond to USD 1,816 million (Fx 0.99).?Roche, Quarterly Report Q3 2019.?https://www.roche.com/investors.htm?.?Last access on?November?4?, 2019?.
More information about:
Edward OliverRudder Finn UK?
+44 (0) 20-7438-3095?
+44 (0) 789-409-5426?
eoliver@ruderfinn.co.uk
